Histopathologische Veränderungen im Sympathicus und ihre Bedeutung

Herzog, Ernst

doi:10.1007/bf01660129

Cited by 19 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They all underscore the constant involvement of structures of the central and peripheral nervous system involved in autonomic regulation. In PD, LB have been amply documented in the hypothalamus [16], the intermediolateral nucleus of the thoracic spinal cord [6,11,12,17], the stellate ganglion [5], the sympathetic ganglia [17,18], the sacral parasympathetic neurones [8,9,20,21], as well as the visceral autonomic nervous system [7,22,23], and they have been considered responsible for some of the autonomic dysfunctions in PD. Profound cardiac sympathetic denervation has been shown in PD patients by sympathetic neuroimaging [24], and post mortem immunostaining of cardiac sympathetic nerves for tyrosine hydroxylase and neurofilament antigens [25,26].…”

Section: Discussionmentioning

confidence: 99%

α‐Synuclein pathology of the spinal and peripheral autonomic nervous system in neurologically unimpaired elderly subjects

Bloch

Probst

Bissig

et al. 2006

Neuropathology Appl Neurobio

300

261

View full text Add to dashboard Cite

Studies on cases with incidental Lewy body disease (ILBD) suggest that alpha-synuclein (alphaSN) pathology of Parkinson's disease (PD) starts in lower brainstem nuclei and in the olfactory bulb. However, medullary structures as the induction site of alphaSN pathology have been questioned as large parts of the nervous system, including the spinal cord and the peripheral autonomic nervous system (PANS), have not been examined in ILBD. Thus, the time course of PD lesions in the spinal cord or PANS in relation to medullary lesions remains unknown. We collected 98 post mortem cases with no reference to PD-associated symptoms on clinical records. alphaSN pathology was found in the central nervous system, including the spinal cord, and in the PANS in 17 (17.3%) cases. alphaSN pathology was encountered in autonomic nuclei of the thoracic spinal cord, brainstem and olfactory nerves in 17/17, in sacral parasympathetic nuclei in 15/16, in the myenteric plexus of oesophagus in 14/17, in sympathetic ganglia in 14/17, and in the vagus nerve in 12/16 cases. In addition to the thoracic lateral horns, a high number of alphaSN lesions was also found in non-autonomic spinal cord nuclei. Considering supraspinal structures our cases corresponded roughly to the recently described sequential order of alphaSN involvement in PD. Our study indicates, however, that the autonomic nuclei of the spinal cord and the PANS belong to the most constantly and earliest affected regions next to medullary structures and the olfactory nerves. A larger cohort of ILBD cases will be needed to pinpoint the precise induction site of alphaSN pathology among these structures.

show abstract

Section: Discussionmentioning

confidence: 99%

α‐Synuclein pathology of the spinal and peripheral autonomic nervous system in neurologically unimpaired elderly subjects

Bloch

Probst

Bissig

et al. 2006

Neuropathology Appl Neurobio

300

261

View full text Add to dashboard Cite

show abstract

“…However, a careful review of the literature reveals that the evidence has been there for nearly 80 years. Herzog first described Lewy bodies in the superior cervical sympathetic ganglia in 1937, 30 and the disease has been known to widely affect the peripheral autonomic nervous system for over 60 years. 31 In the 1980s, the identification of Lewy bodies in the mesenteric plexus of the GI tract provided further evidence for a role of the autonomic system.…”

Section: The Rationale For a Dual Imaging Algorithmmentioning

confidence: 99%

Optimizing Parkinson’s disease diagnosis: the role of a dual nuclear imaging algorithm

Langston

Wiley

Tagliati

2018

npj Parkinson's Disease

View full text Add to dashboard Cite

The diagnosis of Parkinson’s disease (PD) currently relies almost exclusively on the clinical judgment of an experienced neurologist, ideally a specialist in movement disorders. However, such clinical diagnosis is often incorrect in a large percentage of patients, particularly in the early stages of the disease. A commercially available, objective and quantitative marker of nigrostriatal neurodegeneration was recently provided by 123-iodine 123I-ioflupane SPECT imaging, which is however unable to differentiate PD from a variety of other parkinsonian syndromes associated with striatal dopamine deficiency. There is evidence to support an algorithm utilizing a dual neuroimaging strategy combining 123I-ioflupane SPECT and the noradrenergic receptor ligand 123I-metaiodobenzylguanidine (MIBG), which assesses the post-ganglion peripheral autonomic nervous system. Evolving concepts regarding the synucleinopathy affecting the central and peripheral autonomic nervous systems as part of a multisystem disease are reviewed to sustain such strategy. Data are presented to show how MIBG deficits are a common feature of multisystem Lewy body disease and can be used as a unique feature to distinguish PD from atypical parkinsonisms. We propose that the combination of cardiac (MIBG) and cerebral 123I-ioflupane SPECT could satisfy one of the most significant unmet needs of current PD diagnosis and management, namely the early and accurate diagnosis of patients with typical Lewy body PD. Exemplary case scenarios will be described, highlighting how dual neuroimaging strategy can maximize diagnostic accuracy for patient care, clinical trials, pre-symptomatic PD screening, and special cases provided by specific genetic mutations associated with PD.

show abstract

“…What is less well recognized is the long‐standing evidence that PD also extends well beyond the boundaries of the central nervous system. Lewy bodies were first described in sympathetic ganglia by Herzog in 1928,3 and in the myenteric plexus of the gut in the late 1980s 4. Furthermore, it has been well documented that Lewy bodies in the peripheral sympathetic nervous system can occur in the absence of clinically manifest parkinsonism 5…”

Section: Lessons From Neuropathologymentioning

confidence: 99%